Lv1
54 积分 2024-06-20 加入
Engineering IL-2 for immunotherapy of autoimmunity and cancer
1天前
已完结
Engineering IL-2 for immunotherapy of autoimmunity and cancer
11天前
已完结
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
21天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
22天前
已完结
Pharmacokinetic considerations and strategies for antibody-based therapeutics
23天前
已完结
To degrade or not to degrade: mechanisms and significance of endocytic recycling
24天前
已完结
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
1个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
1个月前
已完结
Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling
1个月前
已完结
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
1个月前
已完结
皖公网安备34019202002308
